Approval of Fulyzaq (Crofelemer) to Relieve Symptoms of Diarrhea in HIV/AIDS Patients Taking Antiretroviral Therapy
January 2, 2013
On December 31, 2012, FDA approved Fulyzaq (crofelemer) to relieve symptoms of diarrhea in HIV/AIDS patients taking combination antiretroviral therapy. The recommended dose is one 125 mg delayed-release tablet taken orally two times a day, with or without food. Fulyzaq tablets should not be crushed or chewed. Tablets should be swallowed whole.
Diarrhea is experienced by many HIV/AIDS patients and is a common reason why patients discontinue or switch their antiretroviral therapies. Fulyzaq is indicated in HIV/AIDS patients whose diarrhea is not caused by an infection from a virus, bacteria, or parasite. Patients take Fulyzaq two times a day to manage watery diarrhea due to the secretion of electrolytes and water in the gastrointestinal tract.View Full Article
Visit the FDA's website to find out more about their activities and publications.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)